Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Variable charge Y-linked protein 1 (VCY) is a small, highly charged, nuclear protein encoded by a testis-specific gene family present on both the X and Y chromosomes, expressed exclusively in the nuclei of male germ cells, especially during spermatogenesis[1][3][2]. Members of this gene family share high sequence identity, differing mainly in a repetitive sequence region between X- and Y-linked copies[3][2]. VCY/VCX proteins are enriched in the nuclei and nucleoli of spermatogenic cells and are hypothesized to play a regulatory role in ribosome assembly during spermatogenesis, though their precise biological function remains unknown[1][3][2]. The VCY1 gene has been implicated in spermatogenic failure and is considered part of the cancer/testis antigen repertoire, but no drugs or established mechanisms of action as a therapeutic target are known[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Variable charge Y-linked protein 1 (VCY).